Global Vaccine Safety Summit
Looking to the future of vaccine safety

AGENDA
2 - 3 December 2019

Executive Board Room, World Health Organization Headquarters, Geneva, Switzerland
The Global Vaccine Safety Blueprint was published in 2012 as the first vaccine safety strategy of the Global Vaccine Action Plan (GVAP 2011-2020). Implementation started in 2012 through the Global Vaccine Safety Initiative (GVSI) with active involvement and participation of member states regulators and immunization programs, technical partners, manufacturers and other stakeholders in global vaccine safety.

As we approach the end of the Decade of Vaccines, and with just a couple of years remaining on the GVAP, a new strategy for immunization is under development for endorsement at the 73rd World Health Assembly in May 2020, and a regulatory action plan 2019-2023 has just been released.

**AM**
- Welcome address 09:00-09:20 Ms Szuzanna Jakab
- Address from WHO Director-General 09:20-09:30 Dr Tedros Ghebreyesus
- The Global Vaccine Safety Initiative 09:30-10:00 Dr Mariângela Simão
- Hearing procedures 10:00-10:10 Chair
- Governance and systems development 10:10-11:00 Dr Lee Hampton
- Coffee break 11:00-11:30
- Coordination of Safety Systems 11:30-12:00 Dr Adiela Saldaña Vidal
- Regulatory framework 12:00-12:30 Dr Gopa Raychaudhuri

**PM**
- Lunch 13:00-14:15
- Address message from CDC Principal Deputy Director Dr Anne Schuchat
- Surveillance of adverse events following immunization (AEFI) Professor Dure Samin Akram
- Address from UNICEF Executive Director Ms Henrietta Fore
- Enhanced Vaccine Safety Communication Dr Elisabeth Wilhelm
- Coffee break 15:45-16:15
- Address from Gavi CEO Dr Seth Berkley
- Fragile States and Emergencies Dr Ananda Amarasinghe
- Accountability framework Professor Jim Buttery
- Wrap-up Chair
- Cocktail 18:30
The Global Advisory Committee on Vaccine Safety (GACVS) was established in 1999 to respond promptly, efficiently, and with scientific rigor to vaccine safety issues of potential global importance. The Committee provides independent, authoritative, scientific advice to WHO on vaccine safety issues of global or regional concern with the potential to affect in the short or long term national immunization programmes. Over its 20 years of operation, GACVS has examined the safety of vaccines and their excipients as well as advised on methodological enhancements and guided the development of global vaccine safety strategies.

Objective:
The overall objective of the meeting is to take stock of GACVS’s accomplishments and look towards evolving challenges for 2020 and beyond. Situation papers will be presented and discussed on four areas of interest.

Expected outputs:
A monograph should result from an edited version of each situation paper enhanced with comments from plenary discussions and selected elements from each presentation.
Global Vaccine Safety Summit
Looking to the future of vaccine safety